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Sm_nary The aim of this study was to examine the relationship between the pharmacokinetics of
daunorubicin (DNR), overexpression of P-glycoprotein (Pgp) and treatment response in acute leukaemia.
Twenty-seven patients with acute leukaemia received DNR as part of induction therapy. The plasma and
cellular levels of DNR and its metabolite daunorubicinol (DOL) were determined using high-performance
liquid chromatography. There were no significant differences between patients who went into complete
remission (12/23) compared with those who did not respond for the following pharmacokinetic parameters:
DNR and DOL plasma AUC (area under the curve) and DNR plasma half-life and clearance. There was a
significant difference in the cellular DNR and DOL AUC between responders and non-responders (P<0.02).
Seven patients were Pgp positive and 18 Pgp negative. There was no correlation between patient response and
the presence of Pgp (P>0.1), nor was there any correlation between the cellular concentration of DNR or
DOL and Pgp (P>0.3). To our knowledge this is the first report examining the relationship between DNR
pharmacokinetics, patient response and Pgp expression. Our data indicated that acute leukaemia patients
responding to chemotherapy had higher cellular DNR and DOL than non-responders; also, overexpression of
Pgp appeared not to be the sole explanation for the lower cellular DNR levels as expected from in vitro
studies.
Daunorubicin (DNR) is an anthracycline antibiotic intro-
duced in the late 1960s for the treatment of leukaemia. It has
been one of the major agents used in the treatment of acute
leukaemia. A factor limiting the effectiveness of this drug is
the development of resistance by the leukaemia. In the last 10
years there has been the discovery of multidrug resistance
(MDR) (Pastan & Gottesman, 1987; Bradley et al., 1988;
Kartner & Ling, 1989), in which the development of resis-
tance to one chemotherapeutic agent leads to the resistance
to a number of other chemotherapeutic agents to which the
cultured tumour cells have not been exposed. One of the
agents involved in MDR is DNR. In vitro, MDR is associated
with the presence of a protein called P-glycoprotein (Pgp), and
it has been hypothesised that intracellular cytotoxic agents
are removed from the cell via Pgp, thus decreasing the intra-
cellular concentration and the effectiveness of these drugs.
Although the relationship between cellular drug concentra-
tions and Pgp has been well established in cell lines (Kartner
et al., 1983; Fojo et al., 1985), this relationship has not been
well documented in patients undergoing chemotherapy. We
(Ma et al., 1987) and others, for example Campos et al.
(1992), have shown that the Pgp phenotype is present in
patients with leukaemia. Previous studies have examined the
pharmacokinetics of DNR in patients (Alberts et al., 1971;
Speth et al., 1987; Kokenberg et al., 1988; Paul et al., 1989),
but few have investigated the cellular levels of DNR and its
major cytotoxic metabolite daunorubicinol (DOL) and treat-
ment response. One issue is whether the resistance to DNR is
due simply to altered plasma kinetics resulting in inadequate
cellular DNR concentrations or to a mechanism involving
Pgp. In this study we examined the plasma and cellular
pharmacokinetics of DNR and DOL in patients with acute
leukaemia, in an attempt to elucidate the relationship
between pharmacokinetics, Pgp and patient response.
Materials and methods
Patients
Twenty-seven patients with either acute myeloid leukaemia
(AML) or acute lymphoblastic leukaemia (ALL) were studied
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(14 females and 13 males). Age ranged from 16 years to 79
years with a median of 49 years. The patients were diagnosed
according to the FAB classification and their clinical charac-
teristics at presentation are reported in Table I.
Patients received DNR (David Bull Laboratories, Victoria,
Australia) infused over a 15 min period (Table I) as part of
their induction chemotherapy. For AML patients the
chemotherapy protocol consisted of Ara-C 100mg m-2 day-'
with or without etoposide 75 mgm-2 day-' for 7 days and
DNR 50 mg m-2 for 3 days (in two patients the doses were
reduced because of concern about accumulated cardiotox-
icity). For ALL patients the Hoelzer protocol (Hoelzer et al.,
1984) was used, which consisted of daily prednisolone with
weekly injections of DNR 25 mg m-2 and vincristine over the
first 4 weeks of induction.
Response was determined according to standard criteria as
follows: a complete remission (CR) was defined as a reduc-
tion of blast cells below 5% and a return to normal
haematopoiesis within 4 weeks after the commencement of
chemotherapy; a partial response (PR) was defined as some
reduction of blasts in the original population but without
adequate normal haemopoietic recovery; no response was
recorded when there was no alteration or an increase in the
blasts. For analysis, patients with a partial response were
grouped with those patients that had no response and are
termed non-responders (NRs).
Collection ofblood andsamplepreparations
Blood samples were collected through a central venous
catheter, in glass tubes containing ACDA (acid citrate dex-
trose A). A 10 ml sample of blood was collected and
immediately placed on ice. Samples were taken before DNR
infusion then at 15 min, 30min, 1 h, 1.5 h, 2 h, 4h, 6 h, 8 h,
10 h, 12 h and 24 h post infusion and then daily for 7 days.
Blood samples were centrifuged at 500g for 5 min and the
plasma removed and stored at - 80'C. The red cells were
then removed by the addition of hypotonic lysis buffer
(155 mM ammonium chloride, 10 mM potassium bicarbonate,
100 mM EDTA). The remaining white cells were immediately
washed twice with cold phosphate-buffered saline (PBS) and
resuspended in 1.3 ml of PBS. A small fraction was then
taken for a white cell count and the remainder stored at
- 80'C. Only 14 of the patients had cellular samples stored,
and the blast cell count in these samples had a median of
57% (Table I).
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Table I Patient characteristics
Blasts Dose DNR dose P-glycoprotein
Patient Sex Age Diagnosis WCC (%) (mg) (mg m-2) Other drugs at induction Response % +vefor JSB 1
1 F 55 AML 10.2 78 85 50 Ara-C, VP16 P 0
2 M 31 ALL 8.7 67 45 25 Vcr, Pred, Asp C 0
3 F 28 ALL 8.1 64 40 25 Vcr, Pred, Asp, Mtx C 0
4 F 32 AML 10.9 29 95 50 Ara-C C 100
5 M 68 AML 15.8 3 90 50 Ara-C, VP16 P 100
6 F 56 AML 75.6 100 80 50 Ara-C, VP16 NE 0
7 F 66 ALL 3.8 34 40 25 Vcr, Pred C 0
8 F 62 ALL 94.6 92 40 25 Vcr, Pred, Mtx N NA
9 M 47 AML 17.1 95 90 50 Ara-C, VP16 C 0
10 M 65 ALL 3.6 0 40 25 Vcr, Pred, Asp N NE
11 F 36 ALL 100 88 35 25 C NA
12 M 28 ALL 13.1 47 45 25 Vcr, Pred C 0
13 M 79 AML 198.9 83 85 50 P 20
14 M 56 AML 13.5 68 100 50 Ara-C, VP16 P 100
15 F 46 AML 3.2 10 85 50 Ara-C, VP16 C 0
16 M 16 ALL 6 50 40 25 Vcr, Pred, Asp C 0
17 M 46 R ALL 3.4 31 105 50 Vcr, Pred N 50
18 F 48 AML 26 45 80 50 C 0
19 F 43 AML 4.3 90 75 45 Ara-C NE 0
20 F 42 ALL 2.9 41 50 25 Vcr, Pred, Asp C 0
21 M 19 AML 67.5 70 90 50 Ara-C NE 0
22 F 64 R AML 2 50 55 35 Ara-C, VP16 N 10
23 F 78 AML 39.3 40 80 50 Ara-C N 0
24 M 71 AML 168.4 72 65 30 Ara-C N 0
25 M 41 R AML 1.4 47 100 50 Ara-C, VP16 NE 0
26 F 67 AML 49.8 30 80 50 Ara-C C 100
27 M 36 R ALL 2.4 23 90 50 P 0
AML, acute myeloid leukaemia; R AML, relapsed acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; R ALL, relapsed acute
lymphoblastic leukaemia; C, complete remission; P, partial response; N, no response; NE, not evaluable; NA, not available; Ara-C, cytosine
arabinoside; VP16, etoposide; Pred, prednisolone; Asp, asparaginase; Mtx, methotrexate.
Analysis ofdaunorubicin and daunorubicinol
To 1 ml of plasma was added 50 ll of potassium hydroxide
and 50;lI of adriamycin (ADR) (1 tLgml-') as an internal
standard. The plasma was extracted with 10 ml of dichloro-
methane-isopropanol (9:1) by vortexing for 1 min. The sam-
ples were then centrifuged at 1,600 g for 5 min and the
aqueous phase was removed. The organic phase was transfer-
red to a clean glass tube and evaporated to dryness under
reduced pressure. The dried extract was reconstituted in
150jul of mobile phase (see below) and 50pl injected onto
the high-performance liquid chromatographic (HPLC) system
(see below). The plasma calibration curve ranged from 5 to
120 ng ml-'. The intra-assay and inter-assay coefficients of
variation for DNR at 25 ng ml-' were 13% and 14%, and at
100 ng ml-' were 6% and 14% respectively. The limit of
detection was 5 ng ml-' for both DNR and DOL.
Intracellular DNR and DOL were analysed by taking a
known number of leukaemic cells (0.5-30 x 106 cells) in 1 ml
of PBS. To this was added 100id of 3 M hydrochloric acid in
ethanol and the internal standard ADR (50 ng as for
plasma). The cells were subjected to sonication for 5 min and
extracted as described above. Standard curves were prepared
using cell concentrations of untreated leukaemic cells similar
to those being assayed. The cellular calibration curve ranged
from 5 to 200 ng ml- The inter-assay coefficient ofvariation
was 12%, and the intra-assay coefficient of variation at
25ngml-' was 3.1%, and at 150 ngml-' was 3.7%.
The analyses were performed using a reverse phase C,8
column (Waters Novapak 3.9 x 150 mm, 4jAm). The mobile
phase consisted of 27% acetonitrile and 73% potassium
dihydrogen phosphate (80mM) at a flow rate of 1 ml min-'.
Detection was by fluorescence spectrophotometry at an
excitation of 480 nm and emission of 560 nm.
Detection ofP-glycoprotein
P-glycoprotein was detected by an immuno-alkaline phos-
phatase method, using the anti-P-glycoprotein antibody JSBI
(Ma et al., 1987). In brief, cytospins of patient cells were
prepared from samples taken before the DNR infusion. The
cells were fixed in acetone-ethanol (1:1) for 90 s, and the
antibody JSB1 was applied at a concentration of 13.3jg
ml-' and incubated overnight at 4°C. Normal human serum
was used to block non-specific binding. A non-specific mouse
IgGI and the CEM cell line were used as negative controls
and the drug-resistant cell line VLB 100 as a positive control.
The results are reported as the percentage of blast cells that
were stained by Pgp (Table I).
Calculation ofpharmacokineticparameters
The area under the curve (AUC) was calculated using the
linear trapezoidal rule. To compare patients receiving
different DNR doses, the AUCs were divided by the dose of
DNR received. Standard equations were used to calculate the
plasma half-life and clearance (Rowland & Tozer, 1989).
Statistics
The Wilcoxon signed-rank test was used to compare
differences between DNR and DOL AUCs. The X test was
used to compare the relationship between Pgp and patient
response, and the Mann-Whitney U-test was used for com-
paring differences between responding and non-responding
patients. P<0.05 was considered significant.
Resuts
This study included 27 patients (Table I), of whom 12
achieved complete remission, five had a partial response and
six did not respond to chemotherapy. Four patients could
not be evaluated because they died before a haematological
response could be determined. The pharmacokinetic para-
meters for all patients are given in Table II. There is an
inter-individual variation in both DNR and DOL AUC in
the patients studied. The average plasma concentration-time
curve for DNR and DOL for patients receiving a 50 mg m-2
dose of DNR is shown in Figure la. Figure la shows that
the plasma DOL AUC- 24h levels were significantly higher
than plasma DNR for patients receiving a 50 mg m-2 dose of326 P. GALETTIS et al.
Table H Patent pharmacokinetic parameters
Plasma AUC,24 k
(nghmF)
DNR DOL
247 856
375 886
1235 3328
344 1009
593 1639
559 1544
333
729
756
261
341
288
703
1199
2095
1419
482
899
701
1405
487 1171
DNRplasa
half-life
(h)
4.51
8.70
4.28
10.83
8.03
7.27
6.02
6.93
6.90
13.89
5.98
6.36
11.98
8.29
DNR
clearance
(lh-')
385
240
69
233
135
Cellular AUC0 24k
(ngh 10'- cells)
DNR DOL
122
632
119
111
178
8
127
32
21
62
Celhluar AUCO 24k
(ngh 10-6 cellsmg-' DNR)
DNR DOL
1.28 0.08
7.02 1.41
1.40 0.38
1.39 0.26
2.23 0.78
212 232 50 2.66
255
123
112 84 5 0.99
383 37 10 0.37
308
278
128 66 9 0.73
227 62 8 0.70
0.58
0.06
0.10
0.10
0.09
35 269 1080
30 361 594
5.27
5.51
315 837 5.39
189
95
169
234
202
98
152
278
304
308
553
286
436
373
44.63
4.19
10.24
29.16
33.08
1.74
12.80
163 363 19.41
NR 25 243 1091
NR 25 148 350
13.75
2.21
196 721 7.98
204
180 67 12 1.03
192 67 12 1.03
238
421
237
150
223
408
329
18 9 0.40
125
39
101
31
14
11
3.13
1.11
2.24
286 71 16 1.72
165
270
35 8 0.88
217 35 8 0.88
CR, complete remission; NR, non-responders.
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Fugwe 1 a, Plasma concentration-time curve of daunorubicin
(-) and daunorubicinol (0) in patients (n = 12) receiving a
50mg m-2 dose of daunorubicin. b, Cellular concentration-time
curve of daunorubicin (U) and daunorubicinol (0) in patients
(n=8) receiving a 50mg m2 dose of daunorubicin (mean and
s.d.).
DNR (P<0.003). For patients receiving a 25 mgm2 dose
of DNR the plasma concentrations of DOL were also
significantly higher than DNR (P<0.004) (Table II). Thus,
the plasma DOL AUCOG24k was higher than DNR AUC 24h
irrespective of the dose received by the patient. There were
no signint differences in the plasma AUCO-24h of either
DNR (P>0.3) or DOL (P>0.3) of patients that responded
to treatment compared with those that did not (Table H).
There was also no significant difference in the DNR plasma
half-life (P>0.4) or clarnce (P>0.4) between patients that
responded compared with those that did not (Table II).
The cellular concentration-time curve of patients receiving
a S0mgm-2 dose of DNR is shown in Figure lb, with the
cellular pharmacokinetic parameters given in Table H. The
cellular AUC for DNR was significantly higher in all patients
compared with the metabolite DOL (P<0.001). There was a
significant difference in cellular DNR AUC (P<0.03)
between CR (232 ± 225 ng 106 cells, n = 5) patients and the
NR (62 ± 24 ng 10-6 cells, n = 3) patients that received a
50mg m-2 dose (Figure 2). A similar difference in AUC
(P<0.1) was also seen for DOL in these patients (Table I).
Of the patients receiving a 25 mg m-2 dose of DNR, only 2/9
failed to respond to treatment, and data for cellular DNR
and DOL AUC were available on only one of the non-
responders. Thus, statistical analysis could not be performed
in the patients receiving a 25mgm-2 dose of DNR. The
non-responding patient displayed lower cellular levels of
DNR and DOL than those that responded to treatment
(approximately half the mean AUC values for the complete
responders). Therefore, all patients were analysed by the
cellular concentration of DNR per mg of DNR infused.
DNR cellular concentrations rmained significantly higher
(P<0.02) in the CR (2.24 ± 1.96 ngl106 cells per mg of
DNR given, n = 9) group compared with the NR
(0.80 ± 0.27 ng 10-6 cells per mg DNR given, n = 5) group
Patient
4
9
15
18
26
Average
5
13
14
17
23
27
Average
Response
CR
CR
CR
CR
CR
NR
NR
NR
NR
NR
NR
NR
DNR dose
(mgm 2)
50
50
50
50
50
50
50
50
50
50
50
50
NR
NR
22
24
Average
2
3
7
11
12
16
20
Average
8
10
Average
CR
CR
CR
CR
CR
CR
CR
25
25
25
25
25
25
25
0.18
0.18
0.20
0.78
0.40
0.24
0.40
0.20
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(Figure 3). A similar difference was also seen for DOL
(P<0.02) (Figure 3).
Of the 27 patients studied, seven were Pgp positive and
14 18 Pgp negative patients were evaluable for treatment
response. Two patients (patients 8 and 11) could not be
tested for Pgp because of inadequate samples (Table I). Of
the patients who underwent complete remission, two were
Pgp positive and nine were Pgp negative, and of those
patients not responding to treatment five were Pgp positive
and five were Pgp negative. There was no correlation
between patient response and the presence of Pgp (P>0.1)
found in this study. Also, no significant difference was found
between the cellular AUCs for DNR (P>0.3) or DOL
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Table Relationship betweenP-glycoprotein andintracellularDNR
or DOL [mean ± s.d. (n)]
P-glycoprotein
Positive Negative
DNR 1.22 ± 0.77 (4) 2.17 ± 2.14(8)a
(ng h 10-6 cellsmg-' DNR)
DOL 0.26± 0.35 (4)b 0.44 ± 0.44 (8)b
(ngh 10-6 cellsmg-' DNR)
aP>0.3. bp>0.3
rgp-negative patients (Table 1I). present in the cells ofpatients with acute leukaemia. In view
of our results it appears that the presence and the activity of
this enzyme in leukaemic cells must be low. Incubating the
leukaemic cell line CEM with DNR over 4 h did not produce
any measurable DOL, confirming the lack of or extremely
a obtained in this study on low level of daunorubicin reductase in these cells (unpub-
g DNR showed higher plasma fished results). Furthermore, when the metabolite DOL was
bolite DOL than the parent drug incubated with CEM cells, only 14% of the metabolite was
lar DNR levels than DOL. Our accumulated compared with the amount of DNR that would
revious studies (Speth et al., 1987; be accumulated. Therefore, it appears that the differences
I et al., 1989). DNR is extensively between plasma and cellular concentrations of DNR are due
his is predominantly achieved in to the inability of DOL to cross the cell membrane and the
ductase (daunorubicin reductase) lack of daunorubicin reductase in the cells.
[he fact that the cellular concen- There have been few reports on the correlation of plasma
as very low suggests that there is and cellular DNR pharmacokinetics and clinical response. In
DNR at the cellular level and the present study, no correlation between patient response
he cell membrane. Huffman and and plasma pharmacokinetics was observed. The average
ithat daunorubicin reductase is (± s.d.) plasma half-life and plasma clearance of DNR for all
patients were 11±llh and 238±lOOlh-1 respectively,
which is similar to the values obtained by Speth et al. (1987)
and Kokenberg etal. (1988). Kokenberg et al. (1988) found
that there were no differences between plasma DNR or DOL
AUCs compared with patient response. They also reported
no relationship between any other plasma pharmacokinetic
parameter and patient response. In this study, an incon-
sistency was noted: patients that received a 25 mgm-2 dose
of DNR achieved only approximately one-third of the
plasma AUC of DNR (170 ± 53) compared with those
patients that received 50 mgm2 (517 ± 296). One explana-
tion might be that patients receiving 50 mg m2 DNR also
received Ara-C and VP16 in combination, while those receiv-
ing 25 mg m received prednisolone and vincristine in com-
bination. This suggests that either the combination of Ma-C
10 15 20 25 and VP16 increases the plasma AUC of DNR or pred-
Time (h) nisolone and vincristine decrease the plasma AUCof DNR.
Nearly all chemotherapeutic protocols involve the use of
icentration-time curve in patients more than one agent, however there is no literature available
se of DNR, showing patients who on the pharmacokinetic interactions between DNR and any
n 5) respond to treatment (mean other agent used inchemotherapeutic regimens.
In this study there was a significant difference in both
cellular DNR and DOL levels in those patients who under-
went complete remission compared with those that did not
respond. This is incontrast to the report ofKokenberg etal.
(1988), who found that there was no correlation between any
pharmacokinetic parameter and response to therapy. One
possible explanation for the differences is that Kokenberg et
al. (1988) compared intracellullar concentrations at a single
time point, whereas the cellular concentration for a 24 h
period (AUCOG241h) was analysed in this study. A recent study
by Marie etal.(1993) showed similar findings to this study in
vitro. They found increased cellular DNR concentrations in
patients achieving complete remission compared with those
not responding to treatment. Concerning the other drugs
T used in induction therapy, they were given to both res-
ponders and non-responders, and thus affect both groups
F X 110 t equally. In spite of the variables, i.e. different drug concen-
Cellular DOL trations, different chemotherapy regimens and different types of leukaemia, a significant difference was observed in the
DNR and DOL inpatients that cellular drug concentration between patients responding and !motherapy and those that did not those not responding to chemotherapy, implying that the
ng the 10th, 25th, 50th (median), correlation is independent of these factors. We were unable '<0.02; tP<0.02. to recruit more patients to extend this study owing to the328 P. GALETTIS et al.
change in the clinical practice of the treatment of acute
leukaemia. DNR having been replaced by newer anthracyc-
line analogues (idarubicin) and anthracenes (mitoxantrone).
To our knowledge. this is the first report investigating the
relationship between Pgp and intracellular levels of DNR in
patients. The cellular concentrations of DNR and DOL
tended to be lower in those patients who were Pgp positive
than in those who were not (Table III), but statistically there
was no difference. Overexpression of Pgp might not be the
sole explanation for the lower cellular DNR in patient
leukaemic cells. Further studies are required before this can
be determined. One possible reason for the lower cellular
DNR in patient leukaemic cells could be the presence of
non-Pgp mechanisms of resistance, such as that associated
with the HL 60,ADR cell line (Marsh et al., 1986). In this
drug-resistant cell line there was a decrease in intracellular
drug concentration, but no detectable Pgp. Recently, Krish-
namachary and Center (1993) have demonstrated the
presence of another membrane protein which may be respon-
sible for the decreased cellular drug accumulation present in
the HL 60 ADR cell line. This membrane protein has been
associated with the overexpression of the MRP gene, and this
gene may play a role in patients with acute leukaemia who
do not respond to treatment.
Previous studies examining the relationship between Pgp
and patient response have shown conflicting findings. Chan
et al. (1991) observed a correlation between Pgp and patient
response. Twenty-six out of 31 non-localised neuroblastoma
patients who were Pgp negative had a complete response to
treatment, as compared with 6 of the 13 who were Pgp
positive. Campos et al. (1992) had similar findings with acute
non-lymphoblastic leukaemia in which complete remiosion
rates were significantly lower in Pgp-positive patients (23 71.
32%) than in Pgp-negative patients (64 79. 81%). Marie et
al. (1991) and Pirker et al. (1991) also found a correlation
between Pgp (mdrl gene expression) and patient response.
Marie et al. (1991) observed a complete remission of 67% in
patients with undetectable mdrl expression, compared with
29% in patients with increased expression. Pirker et al.
(1991) found the complete remission rate to be 89% in mdrl
RNA-negative patients and 53% in mdrl-positive patients. In
contrast to the above findings, Holmes et al. (1989) estab-
lished that the overexpression of the Pgp gene was not an
important mechanism in previously untreated AML. In that
study elevated levels of mdrl were seen in two out of eight
patients with untreated AML, five out of eight with refrac-
tory AML and four out of five patients with secondary
AML. Rothenberg et al. (1989) observed that eight out of
nine patients with ALL at presentation had low levels of
mdrl mRNA. In five patients at primary relapse, none had
evidence of mdrl overexpression and 3 out of 15 patients
with multiple relapses had elevated mdrl expression. They
concluded that Pgp might play a role in some cases of drug
resistance and that other mechanisms of resistance must
exist. We have found no significant relationship between Pgp
and patient response. Of the patients in this study, 17 out of
21 were previously untreated. Twelve of these patients were
Pgp negative. with nine achieving complete remission (75%),
and five were Pgp positive (2 5 achieving CR. 40%). Of the
four patients that were previously treated. two were Pgp
positive and two were Pgp negative. None of these patients
responded to treatment. Our findings are similar to those of
Rothenberg et al. (1989), who showed low levels of Pgp at
induction but higher levels of Pgp in multiple relapse
patients.
In conclusion, a correlation between the intracellular DNR
and DOL concentrations and patient response was observed
in this study. The relationship between Pgp and intracellular
drug concentrations was also examined. Although there was
no statistical correlation between Pgp'and intracellular drug
concentrations, there was a tendency for patients who were
Pgp positive to have decreased intracellular concentrations of
DNR and DOL. A higher proportion of previously treated
patients were Pgp positive, but no correlation was found
between Pgp and patient response. suggesting that mech-
anism(s) of drug resistance other than Pgp are important in
clinical resistance to DNR.
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